Fiona Marshall at ARDD2026: Reimagining Drug Discovery Through the Lens of Aging Biology

Fiona Marshall at ARDD2026: Reimagining Drug Discovery Through the Lens of Aging Biology

Title history
  • Fiona Marshall at ARDD2026: Reimagining Drug Discovery Through the Lens of Aging Biology — observed on 20261113-2201 UTC (YouTube)
🎙 Fiona Marshall (Novartis) 👥 9K 📅 November 13, 2026 ⏱ 28 min 👁 109 📄 expert opinion 🧭 2026-11-13
Available in: English (current) Français

Keywords

aging biologyNovartisosteoarthritissarcopeniaresilience

Summary

Fiona Marshall, Chief Scientific Officer at Novartis, presents at the 13th ARDD meeting. She shares lessons from two failed phase 2 trials targeting single aging pathways: osteoarthritis regeneration via LNA043 and sarcopenia via bimagrumab. Both showed tissue regrowth but no improvement in patient-relevant outcomes like pain or mobility, leading to a strategic shift. Novartis now adopts a systems-based approach, viewing aging as an interconnected network of hallmarks. The new department DARE (Diseases of Aging and Regenerative Medicine) integrates longitudinal human data, including genetic, clinical, and lifestyle factors, to identify causal drivers. Emphasis is placed on resilience mechanisms observed in healthy aged individuals and the powerful protective effect of exercise. The talk highlights the need for large-scale data and AI to uncover novel drug targets, and collaboration with BioAge. The ultimate goal is to increase healthspan by targeting pathways that span multiple diseases, using composite endpoints and regulatory approval grounded in human biology.

152 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides valuable, pragmatic insights from two clinical failures that demonstrate the insufficiency of single-target regenerative approaches. The argumentation is logically structured: from concrete examples to the conclusion that a systems-level understanding is necessary. The speaker uses data from trials and epidemiological evidence to support the shift. The assertion that aging is a major risk factor and that exercise has a profound impact is well-supported. The call for longitudinal data and AI is compelling, though the presentation remains corporate and may overlook some academic nuances.

Scientific Rigor, Source Quality, Title Accuracy

Rigor is moderate: the speaker references specific trials (LNA043, bimagrumab) and collaborations (BioAge, Crick Institute) but does not provide detailed citations or data in the video. The title matches the content precisely. The description lists organizational links only, not scientific references, so source quality relies on the speaker’s credibility. The talk is a high-level overview rather than a rigorous peer-reviewed presentation, but the insights are grounded in real clinical experience.

171 words

Title / Content Match

The title accurately reflects the content: the talk focuses on reinterpreting drug discovery using aging biology, including examples of past failures and a new systems-based approach.

Quality & Reliability

8/10

Credible industry perspective from Novartis' executive, offering direct experience from two phase 2 clinical trials. However, it is a corporate viewpoint without independent peer review in the video itself.

Key Moments

Cited Sources

Contribution & Novelties

The talk contributes a realistic industry perspective on the failure of single-target aging interventions, advocating for a systems-based approach grounded in longitudinal human data. It emphasizes resilience mechanisms and the role of exercise, suggesting new avenues for target discovery.

Pour aller plus loin :

  • Hallmarks of Aging (Wikipedia) — Provides the framework referenced in the talk for understanding aging as interconnected biological processes.
  • Healthspan (Wikipedia) — Defines the concept of healthy aging duration, central to the goal of increasing healthspan over lifespan.
  • BioAge Labs Website — Collaborating company mentioned for longitudinal data and exercise biology research (URL likely correct as company homepage).

102 words

Radar Profile

The scores show a moderate profile: quantity and reliability are relatively high, while technical level and quality of information are slightly lower, indicating a high-level strategic talk rather than a deep technical deep-dive.

Reliability 8/10